var data={"title":"Hepatopulmonary syndrome in adults: Natural history, treatment, and outcomes","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Hepatopulmonary syndrome in adults: Natural history, treatment, and outcomes</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/contributors\" class=\"contributor contributor_credentials\">Paul A Lange, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/contributors\" class=\"contributor contributor_credentials\">James K Stoller, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/contributors\" class=\"contributor contributor_credentials\">Jess Mandel, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/contributors\" class=\"contributor contributor_credentials\">Geraldine Finlay, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 21, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H19912623\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hepatopulmonary syndrome (HPS) is characterized by the triad of abnormal arterial oxygenation caused by intrapulmonary vascular dilatations (IPVD) in the setting of liver disease, portal hypertension, or congenital portosystemic shunts [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/1,2\" class=\"abstract_t\">1,2</a>]. </p><p>The natural history, treatment, and outcomes of HPS are reviewed here. The epidemiology, pathophysiology, clinical manifestations, and diagnostic evaluation are discussed separately. (See <a href=\"topic.htm?path=hepatopulmonary-syndrome-in-adults-prevalence-causes-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Hepatopulmonary syndrome in adults: Prevalence, causes, clinical manifestations, and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3217399\"><span class=\"h1\">NATURAL HISTORY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>HPS is typically a progressive disorder, the presence of which worsens the prognosis of patients with cirrhosis and probably other liver diseases [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/1,3-7\" class=\"abstract_t\">1,3-7</a>]. The cause of death among patients with HPS tends to be multifactorial and related to complications of underlying liver disease (eg, hepatic failure, multisystem organ failure due to sepsis, hepatocellular cancer, gastrointestinal bleeding) rather than from HPS-related hypoxemic respiratory failure [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/1,3,4\" class=\"abstract_t\">1,3,4</a>]. Spontaneous resolution of HPS without treatment is unlikely. These conclusions are derived from the following studies:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>One observational study of 138 liver transplant candidates reported a higher mortality in patients with HPS compared with case-matched controls (78 versus 43 percent) [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/4\" class=\"abstract_t\">4</a>]. Similarly, patients with HPS had a lower median survival (24 versus 87 months) and lower five-year survival (23 versus 63 percent).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A single center prospective study of 316 patients referred for liver transplantation reported that compared with patients without HPS, patients with HPS had a nonsignificant increase in waitlist mortality (24 versus 16 percent) and a slightly lower pre-liver transplant survival (35 versus 42 months) [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/5\" class=\"abstract_t\">5</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a prospective study of 111 patient with cirrhosis, those with HPS had a lower median survival than those without HPS (11 versus 41 months), even when adjusted for severity of underlying liver disease [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/3\" class=\"abstract_t\">3</a>]. HPS was an independent predictor of survival. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A retrospective series of 22 patients with HPS, most of whom had severe HPS, reported an overall mortality of 41 percent, occurring, on average, 2.5 years after diagnosis [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/6\" class=\"abstract_t\">6</a>].</p><p/><p>Although oxygenation usually worsens over time (mean decline of 5.2 mmHg per year [range 0.4 to 8.3 mmHg per year]) [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/4\" class=\"abstract_t\">4</a>], it is rare for progressive hypoxemic respiratory failure to be the primary cause of death. </p><p class=\"headingAnchor\" id=\"H19913348\"><span class=\"h1\">TREATMENT AND PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The only definitive therapy for patients with HPS is liver transplantation, which is reserved for those with severe or very severe HPS (<a href=\"image.htm?imageKey=PULM%2F109898\" class=\"graphic graphic_table graphicRef109898 \">table 1</a>). Other than long-term supplemental oxygen, there are no effective medical therapies for HPS, although many approaches have been attempted to improve gas exchange and decrease hypoxemia (<a href=\"image.htm?imageKey=PULM%2F52526\" class=\"graphic graphic_table graphicRef52526 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/1,8\" class=\"abstract_t\">1,8</a>]. Rarely, resolution of HPS in response to treating the underlying acute liver disease has been reported (eg, steroids for patients with granulomatous hepatitis) [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/9\" class=\"abstract_t\">9</a>]. Grading disease severity is discussed separately. (See <a href=\"topic.htm?path=hepatopulmonary-syndrome-in-adults-prevalence-causes-clinical-manifestations-and-diagnosis#H3218117\" class=\"medical medical_review\">&quot;Hepatopulmonary syndrome in adults: Prevalence, causes, clinical manifestations, and diagnosis&quot;, section on 'Grading disease severity'</a>.)</p><p class=\"headingAnchor\" id=\"H958610991\"><span class=\"h2\">Mild to moderate hepatopulmonary syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most patients in this category require clinical monitoring for disease progression, and some may need supplemental oxygen, when indicated. &#160;</p><p class=\"headingAnchor\" id=\"H1723871244\"><span class=\"h3\">Observation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most patients with mild to moderate HPS require monitoring every 6 to 12 months with pulse oximetry and, when indicated, arterial blood gas analysis to determine worsening HPS that may prompt a more aggressive treatment strategy with liver transplantation <span class=\"nowrap\">and/or</span> oxygen supplementation, early in the course of disease progression. Transthoracic contrast echocardiography does not need to be repeated to monitor shunt. (See <a href=\"topic.htm?path=hepatopulmonary-syndrome-in-adults-prevalence-causes-clinical-manifestations-and-diagnosis#H3217592\" class=\"medical medical_review\">&quot;Hepatopulmonary syndrome in adults: Prevalence, causes, clinical manifestations, and diagnosis&quot;, section on 'Diagnostic evaluation'</a>.)</p><p class=\"headingAnchor\" id=\"H1079173587\"><span class=\"h3\">Oxygen supplementation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with mild to moderate HPS with resting PaO<sub>2</sub> &gt;55 mmHg (7.3 kPa) or peripheral arterial saturation &gt;88 percent do not fulfill the criteria for oxygen supplementation (<a href=\"image.htm?imageKey=PULM%2F76543\" class=\"graphic graphic_table graphicRef76543 \">table 3</a>) unless exercise-induced or nocturnal hypoxemia is present. Thus, in this population, we typically perform periodic six-minute walk testing and nocturnal oximetry. (See <a href=\"topic.htm?path=long-term-supplemental-oxygen-therapy\" class=\"medical medical_review\">&quot;Long-term supplemental oxygen therapy&quot;</a> and <a href=\"topic.htm?path=overview-of-pulmonary-function-testing-in-adults#H13496651\" class=\"medical medical_review\">&quot;Overview of pulmonary function testing in adults&quot;, section on 'Six-minute walk test'</a>.) </p><p class=\"headingAnchor\" id=\"H4166728594\"><span class=\"h2\">Severe or very severe hepatopulmonary syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most patients in this category require supplemental oxygen therapy and should be evaluated for liver transplantation.</p><p class=\"headingAnchor\" id=\"H3022257422\"><span class=\"h3\">Oxygen supplementation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Long-term supplemental oxygen therapy (LTOT) is the most frequently recommended therapy for patients with severe or very severe HPS [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/1\" class=\"abstract_t\">1</a>]. Indications for oxygen supplementation are similar to those used for patients with hypoxemia due to chronic pulmonary disease (<a href=\"image.htm?imageKey=PULM%2F76543\" class=\"graphic graphic_table graphicRef76543 \">table 3</a>), the details of which are provided separately. (See <a href=\"topic.htm?path=long-term-supplemental-oxygen-therapy\" class=\"medical medical_review\">&quot;Long-term supplemental oxygen therapy&quot;</a>.)</p><p>LTOT is not a cure for HPS. LTOT only improves features related to intrapulmonary vascular shunts (eg, dyspnea, fatigue, desaturation) in patients who are hypoxemic due to HPS, although the only evidence that supports this conclusion is indirect evidence extrapolated from patients with hypoxemia from other lung diseases (eg, chronic obstructive pulmonary disease) and anecdotal clinical observations. Controlled clinical trials comparing LTOT to no therapy in HPS have not been performed. </p><p class=\"headingAnchor\" id=\"H599838807\"><span class=\"h3\">Liver transplantation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with HPS and a partial arterial pressure of oxygen (PaO<sub>2</sub>) &lt;60 mmHg (8 kPa; ie, severe and very severe HPS (<a href=\"image.htm?imageKey=PULM%2F109898\" class=\"graphic graphic_table graphicRef109898 \">table 1</a>)) should be evaluated for liver transplantation (LT). This strategy is based upon observational studies that demonstrate complete or near complete resolution of HPS with improved oxygenation and shunt in the majority (about 80 percent) of patients within the initial 6 to 12 months [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/4,10-21\" class=\"abstract_t\">4,10-21</a>], and studies that report a similar mortality in those with and without HPS who undergo LT [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/5,22-24\" class=\"abstract_t\">5,22-24</a>]. In support of this approach, the 2013 <a href=\"http://www.aasld.org/sites/default/files/guideline_documents/141020_Guideline_Evaluation_Adult_LT_4UFb_2015.pdf&amp;token=xVLmpBUAPpI7KDGwQ5oLoU3/nKQ/5jMRcENm2gvc+ejRYf2ajYnTkZSJRUZFNF3hLbxbCLjqJ2Cad8ws75xj9QDG1PtNkxQlv9LB3TMAzOc+t1qxhsMVTU6Ye/NwBLLIObGdePHs06+5RRc7VZiuSQ==&amp;TOPIC_ID=16175\" target=\"_blank\" class=\"external\">American Association for the Study of Liver Disease and American Society of Transplantation Practice Guidelines</a> and the International Liver Transplant Society practice guidelines recommend an expedited referral and evaluation for LT for patients with severe HPS [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/2,25\" class=\"abstract_t\">2,25</a>]. (See <a href=\"topic.htm?path=model-for-end-stage-liver-disease-meld#H16431878\" class=\"medical medical_review\">&quot;Model for End-stage Liver Disease (MELD)&quot;, section on 'Standard MELD exceptions in liver transplantation'</a> and <a href=\"topic.htm?path=liver-transplantation-in-adults-patient-selection-and-pretransplantation-evaluation\" class=\"medical medical_review\">&quot;Liver transplantation in adults: Patient selection and pretransplantation evaluation&quot;</a>.)</p><p>Since some patients with mild liver disease who have advanced HPS may not be eligible for LT (based upon the severity of their underlying liver disease as assessed by Model for End-Stage Liver Disease (MELD) points [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/26\" class=\"abstract_t\">26</a>]), the Organ Procurement Transplant <span class=\"nowrap\">Network/United</span> Network for organ sharing (UNOS) policy assigns a standard MELD exception score of 22 for patients with evidence of intrapulmonary shunting and a room air PaO<sub>2</sub> &lt;60 mmHg (8 kPa), with a 10 percent mortality equivalent increase in points every three months if the PaO<sub>2</sub> remains &lt;60 mmHg. Some also allocate increased exception scores in those with a PaO<sub>2</sub> of 50 mmHg (6.7 kPa) [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/2\" class=\"abstract_t\">2</a>]. (See <a href=\"topic.htm?path=model-for-end-stage-liver-disease-meld#H16431878\" class=\"medical medical_review\">&quot;Model for End-stage Liver Disease (MELD)&quot;, section on 'Standard MELD exceptions in liver transplantation'</a> and <a href=\"topic.htm?path=liver-transplantation-in-adults-patient-selection-and-pretransplantation-evaluation\" class=\"medical medical_review\">&quot;Liver transplantation in adults: Patient selection and pretransplantation evaluation&quot;</a>.)</p><p>Although successful outcomes have been reported in patients with HPS who have received living donor LT, cadaveric LT remains the primary graft type for this population [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/27-29\" class=\"abstract_t\">27-29</a>]. </p><p>Pathologic changes in the lungs after LT are poorly studied. One older post-mortem study reported improvement or resolution of the pathologic changes and collagen tissue deposition in capillary and venule walls [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/30\" class=\"abstract_t\">30</a>]. Further studies are required to understand the mechanism of resolution. </p><p class=\"headingAnchor\" id=\"H458149789\"><span class=\"h4\">Mortality</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Liver transplantation appears to improve mortality among patients with HPS and is similar to those who undergo LT who do not have HPS:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In one observational study of 61 patient with HPS, mortality was higher in those who did not undergo LT compared with those who had LT (78 versus 21 percent) [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/4\" class=\"abstract_t\">4</a>]. Among patients who underwent liver transplantation, those with HPS had a five-year survival rate of 76 percent, which was not significantly different from the five-year survival of patients without HPS [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/4\" class=\"abstract_t\">4</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In another observational study of 59 transplant recipients, similar short-term survival (77 versus 68 percent) and long-term survival (64 versus 60 percent) was reported in those with and without HPS; survival was independent of the severity of HPS [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/22\" class=\"abstract_t\">22</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a series of 106 patients with HPS that compared outcomes in patients who underwent liver transplantation in the pre- and post- MELD exception eras, post-transplant survival was consistently better in the post-MELD era: 92 versus 71 percent at one year, 88 versus 67 percent at three years, and 88 versus 67 percent at five years [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/23\" class=\"abstract_t\">23</a>]. </p><p/><p>The early postoperative period tends to be the most dangerous, and patients who survive this period tend to do well [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/10,11\" class=\"abstract_t\">10,11</a>]. In one observational study, patients with HPS who survived the initial 10 weeks following transplantation subsequently survived for at least one year. </p><p>The etiologies associated with postoperative death are unknown but may be due to refractory postoperative hypoxemia, portal venous thrombosis, intracranial events, and multiorgan failure [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/31\" class=\"abstract_t\">31</a>]. (See <a href=\"#H306139326\" class=\"local\">'Refractory hepatopulmonary syndrome'</a> below and <a href=\"topic.htm?path=liver-transplantation-in-adults-long-term-management-of-transplant-recipients\" class=\"medical medical_review\">&quot;Liver transplantation in adults: Long-term management of transplant recipients&quot;</a> and <a href=\"topic.htm?path=infectious-complications-in-liver-transplantation\" class=\"medical medical_review\">&quot;Infectious complications in liver transplantation&quot;</a> and <a href=\"topic.htm?path=liver-transplantation-diagnosis-of-acute-cellular-rejection\" class=\"medical medical_review\">&quot;Liver transplantation: Diagnosis of acute cellular rejection&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H708385551\"><span class=\"h4\">Prognostic factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Severe hypoxemia may predict a worse outcome in patients with HPS who undergo LT. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Pre-transplantation hypoxemia</strong> &ndash; Despite conflicting data, we and others consider that patients with severe deficits in oxygenation are high risk candidates for LT, but that this should not preclude them from undergoing LT [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/2\" class=\"abstract_t\">2</a>]. Conflicting data may relate to altered transplantation strategies due to MELD exception criteria or to differences in practice between centers of excellence. (See <a href=\"#H599838807\" class=\"local\">'Liver transplantation'</a> above and <a href=\"topic.htm?path=model-for-end-stage-liver-disease-meld#H16431878\" class=\"medical medical_review\">&quot;Model for End-stage Liver Disease (MELD)&quot;, section on 'Standard MELD exceptions in liver transplantation'</a>.)</p><p/><p class=\"bulletIndent1\">Several studies have reported that severe hypoxemia (45 to 50 mmHg; 6.0 to 6.7 kPa) pre-liver transplantation is associated with an increased post-transplant mortality [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/10,16,24\" class=\"abstract_t\">10,16,24</a>], although the exact cut-off is unclear:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In a prospective evaluation of 24 patients with cirrhosis and LT, a preoperative room air arterial oxygen tension (PaO<sub>2</sub>) &le;50 mmHg alone or in combination with a shunt fraction &ge;20 percent on macroaggregated albumin scanning (MAA) were strong predictors of postoperative mortality [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/10\" class=\"abstract_t\">10</a>]. (See <a href=\"topic.htm?path=hepatopulmonary-syndrome-in-adults-prevalence-causes-clinical-manifestations-and-diagnosis#H3217606\" class=\"medical medical_review\">&quot;Hepatopulmonary syndrome in adults: Prevalence, causes, clinical manifestations, and diagnosis&quot;, section on 'Macroaggregated albumin scanning'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In a retrospective cohort study, patients on the liver transplant wait list were analyzed using data derived from the United Network for Organ Sharing (UNOS) from 2002 to 2012 [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/24\" class=\"abstract_t\">24</a>]. Rates of three-year unadjusted post-transplantation survival were lower in those with a PaO<sub>2</sub> &le;44 mmHg compared with those who had a PaO<sub>2</sub> &gt;44 mmHg (68 versus 84 percent). </p><p/><p class=\"bulletIndent1\">In contrast, other observational studies published after instituting the MELD exception criteria have demonstrated that severe hypoxemia or shunt do not predict mortality in this population [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/12,23\" class=\"abstract_t\">12,23</a>]. </p><p/><p class=\"bulletIndent1\">Little is known about whether postoperative improvement in oxygenation can be predicted, although studies suggest that severe hypoxemia or a higher baseline MAA shunt fraction was associated with a lower rate of postoperative improvement in oxygenation and greater need for long term oxygen supplementation [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/12,13,23,32\" class=\"abstract_t\">12,13,23,32</a>]. Severe hypoxemia may also predict longer recovery and hospital length of stay. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Others</strong> &ndash; Other prognostic factors that predict outcome in this population are poorly studied but some observational studies report that severity of underlying liver disease, age, and elevated BUN may contribute [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/3\" class=\"abstract_t\">3</a>]. </p><p/><p class=\"headingAnchor\" id=\"H1666972769\"><span class=\"h4\">Oxygenation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The abnormalities of gas exchange improve or resolve in approximately 80 percent of patients following liver transplantation, although it is uncertain whether or not gas exchange abnormalities in these studies were solely due to shunt [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/4,10-12,14-21,33\" class=\"abstract_t\">4,10-12,14-21,33</a>]. In an observational study of 74 consecutive patients with chronic liver disease who underwent a comprehensive cardiopulmonary assessment before and after LT, 50 percent had an abnormal alveolar-arterial (A-a) oxygen gradient (defined as &ge;15 mmHg) and 22 percent were hypoxemic (defined as a PaO<sub>2</sub> &lt;80 mmHg) before transplantation [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/21\" class=\"abstract_t\">21</a>]. Following transplantation, the mean PaO<sub>2</sub> increased (from 89 to 94 mmHg) and the mean A-a gradient decreased (from 16 to 8 mmHg). However, the diffusion capacity of carbon monoxide (DLCO) may not improve after liver transplantation, suggesting that subclinical pulmonary vascular changes persist [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/34\" class=\"abstract_t\">34</a>].</p><p>The time course by which HPS improves or resolves after liver transplantation is variable. Some studies have demonstrated improvement in the shunt fraction and hypoxemia within days after liver transplantation, while others have demonstrated improvement over 2 to 14 months [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/4,5,17,35-37\" class=\"abstract_t\">4,5,17,35-37</a>]. This wide variation may be due, at least in part, to the studies testing oxygenation at different intervals after transplantation. It may also reflect variability among patients in how much of their hypoxemia is due to ventilation-perfusion mismatch rather than intrapulmonary shunting (it has been hypothesized that the likelihood of improving oxygenation after liver transplantation is greater when the principal mechanism of hypoxemia is ventilation-perfusion mismatching) [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/38\" class=\"abstract_t\">38</a>] or how much vascular remodeling has occurred (it has been hypothesized that vascular remodeling may be a more important cause of gas exchange abnormalities than NO-dependent vasodilatation) [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/39\" class=\"abstract_t\">39</a>].</p><p>Intraoperative and postoperative management should focus on continuous monitoring of peripheral and central oxygenation while the patient is mechanically ventilated in the supine position, preferably using a lung protective strategy. Clinicians should be careful not to over resuscitate or over diurese this group. Management strategies for severe postoperative hypoxemia are discussed below. (See <a href=\"topic.htm?path=pulse-oximetry\" class=\"medical medical_review\">&quot;Pulse oximetry&quot;</a> and <a href=\"topic.htm?path=mechanical-ventilation-of-adults-in-acute-respiratory-distress-syndrome\" class=\"medical medical_review\">&quot;Mechanical ventilation of adults in acute respiratory distress syndrome&quot;</a> and <a href=\"#H306139326\" class=\"local\">'Refractory hepatopulmonary syndrome'</a> below.) </p><p class=\"headingAnchor\" id=\"H1702366810\"><span class=\"h4\">Follow-up</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are no clear guidelines regarding follow-up measures in HPS patients after LT other than periodic pulse oximetry and routine transplant protocols; contrast echocardiography is not necessary unless indicated for another reason. Supplemental oxygen may be discontinued when the resting PaO<sub>2</sub> is &gt;55 mmHg (7.3 kPa) <span class=\"nowrap\">and/or</span> there is no sleep- or exercise-induced requirement. (See <a href=\"topic.htm?path=liver-transplantation-in-adults-long-term-management-of-transplant-recipients\" class=\"medical medical_review\">&quot;Liver transplantation in adults: Long-term management of transplant recipients&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H306139326\"><span class=\"h2\">Refractory hepatopulmonary syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Refractory HPS applies to patients who fail to improve after LT or patients who develop recurrent hypoxemia post LT. This population should be evaluated for the spontaneous recurrence of HPS using the same strategy outlined prior to LT (see <a href=\"topic.htm?path=hepatopulmonary-syndrome-in-adults-prevalence-causes-clinical-manifestations-and-diagnosis#H3217592\" class=\"medical medical_review\">&quot;Hepatopulmonary syndrome in adults: Prevalence, causes, clinical manifestations, and diagnosis&quot;, section on 'Diagnostic evaluation'</a>) as well as for the development of portopulmonary hypertension, <span class=\"nowrap\">and/or</span> other diseases that may be contributing to hypoxemia (eg, pulmonary arteriovenous malformations) [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/40,41\" class=\"abstract_t\">40,41</a>]. Options in this population are limited to maximizing oxygen supplementation (eg, high-flow oxygen, transtracheal oxygen) <span class=\"nowrap\">and/or</span> cautious trials of less well <span class=\"nowrap\">validated/investigational</span> therapies. For patients with severe progressive HPS who are not candidates for LT, or patients who cannot be adequately oxygenated with supplemental oxygen due to significant shunt, therapies are similarly limited. (See <a href=\"#H2506314191\" class=\"local\">'Investigational'</a> below.) </p><p>Severe post-transplant hypoxemia (defined as 100 percent oxygen required to maintain saturation &ge;85 percent) is seen in 6 to 21 percent of patients and is a common cause of mortality following LT [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/10,42,43\" class=\"abstract_t\">10,42,43</a>]. Management strategies include placing the patient in the Trendelenburg position [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/44\" class=\"abstract_t\">44</a>], inhaled <a href=\"topic.htm?path=epoprostenol-drug-information\" class=\"drug drug_general\">epoprostenol</a> [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/43\" class=\"abstract_t\">43</a>], inhaled <a href=\"topic.htm?path=nitric-oxide-drug-information\" class=\"drug drug_general\">nitric oxide</a> [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/45\" class=\"abstract_t\">45</a>], <a href=\"topic.htm?path=methylene-blue-drug-information\" class=\"drug drug_general\">methylene blue</a> [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/46\" class=\"abstract_t\">46</a>], embolization of pulmonary arteriovenous malformations (if present) [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/47\" class=\"abstract_t\">47</a>], and extracorporeal life support [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/48\" class=\"abstract_t\">48</a>]. A choice among these therapies is institution-dependent and should probably start with the least invasive strategy and escalate to riskier or combination therapies [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/42\" class=\"abstract_t\">42</a>].</p><p>Uncommonly, post-LT resolution of HPS has been associated with the development of portopulmonary hypertension (POPH), which can be managed in a manner similar to non-HPS-associated POPH. (See <a href=\"topic.htm?path=portopulmonary-hypertension#H10\" class=\"medical medical_review\">&quot;Portopulmonary hypertension&quot;, section on 'Treatment'</a>.)</p><p class=\"headingAnchor\" id=\"H1624424311\"><span class=\"h2\">Other therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rare case reports of miscellaneous therapies have been published. As examples:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An isolated case of severe HPS in response to steroids was reported in a patient with granulomatous hepatitis [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/9\" class=\"abstract_t\">9</a>], suggesting that monitoring patients with HPS who are undergoing active therapy for their underlying liver disease is prudent. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Similarly, case reports of HPS resolution have been published in response to inferior vena cava (IVC) stenting (in patients with HPS and a spontaneous IVC-portal vein shunt) and ligation of congenital portosystemic shunts (eg, Abernethy malformations associated with HPS have resulted in resolution of HPS) [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/49,50\" class=\"abstract_t\">49,50</a>]. &#160;</p><p/><p class=\"headingAnchor\" id=\"H2506314191\"><span class=\"h1\">INVESTIGATIONAL</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Various interventions and medications have been tried for patients with HPS, including transjugular intrahepatic portosystemic shunt (TIPS), coil embolization, and vasoactive medications, none of which has clear benefit.</p><p class=\"headingAnchor\" id=\"H2056034072\"><span class=\"h2\">Transjugular intrahepatic portosystemic shunt</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The reduction of portal pressures by TIPS placement is an intervention that has been associated with improvement of HPS in several case reports [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/51-57\" class=\"abstract_t\">51-57</a>]. However, we do not advocate routine TIPS placement in patients with HPS, because clinical outcomes have been variable [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/8,56,58\" class=\"abstract_t\">8,56,58</a>]. In addition, there is a risk that TIPS may worsen HPS by increasing the hyperkinetic state, leading to more pulmonary vasodilatation, shunting, and hypoxemia. </p><p class=\"headingAnchor\" id=\"H2558039825\"><span class=\"h2\">Embolization</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rare patients with HPS have large intrapulmonary vascular dilatations (IPVDs; eg, type II lesions), which are akin to pulmonary arteriovenous malformations (identifiable as contrast-enhanced nodular densities on CT imaging). Such lesions may be amenable to embolization, with case reports suggesting modest improvements in oxygenation with this procedure (<a href=\"image.htm?imageKey=RADIOL%2F89203\" class=\"graphic graphic_diagnosticimage graphicRef89203 \">image 1</a>) [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/59,60\" class=\"abstract_t\">59,60</a>]. (See <a href=\"topic.htm?path=transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications\" class=\"medical medical_review\">&quot;Transjugular intrahepatic portosystemic shunts: Indications and contraindications&quot;</a> and <a href=\"topic.htm?path=hepatopulmonary-syndrome-in-adults-prevalence-causes-clinical-manifestations-and-diagnosis#H3958807146\" class=\"medical medical_review\">&quot;Hepatopulmonary syndrome in adults: Prevalence, causes, clinical manifestations, and diagnosis&quot;, section on 'Contrast pulmonary angiography'</a> and <a href=\"topic.htm?path=therapeutic-approach-to-adult-patients-with-pulmonary-arteriovenous-malformations\" class=\"medical medical_review\">&quot;Therapeutic approach to adult patients with pulmonary arteriovenous malformations&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H4182446133\"><span class=\"h2\">Vasoactive medications</span></p><p class=\"headingAnchor\" id=\"H940337831\"><span class=\"h3\">Garlic (allium sativum)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Garlic (Allium sativum) is thought to decrease <a href=\"topic.htm?path=nitric-oxide-drug-information\" class=\"drug drug_general\">nitric oxide</a> synthesis, thereby acting as a potential therapy for HPS. As an example, one prospective randomized, placebo-controlled trial evaluated the effects of oral garlic supplementation (1 to 2 <span class=\"nowrap\">g/m<sup>2</sup>/day)</span> in 41 patients with HPS [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/61\" class=\"abstract_t\">61</a>]. After nine months, compared with placebo, garlic supplementation resulted in a three-fold increase in baseline arterial oxygen levels and a decrease in alveolar-arterial oxygen gradient. Reversal of HPS was observed in 14 of 21 patients treated with garlic compared with only 1 of 20 patients in the placebo group (67 versus 5 percent). Mortality was also lower among patients receiving garlic (10 versus 35 percent).</p><p class=\"headingAnchor\" id=\"H2560738277\"><span class=\"h3\">Others</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Agents that have been tested in animal models and appear promising include <a href=\"topic.htm?path=pentoxifylline-drug-information\" class=\"drug drug_general\">pentoxifylline</a> (a nonspecific phosphodiesterase inhibitor with inhibitory effects on TNF-alpha synthesis) and quercetin (a flavonoid antioxidant) [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/62,63\" class=\"abstract_t\">62,63</a>]. Two small prospective, open-label studies of pentoxifylline (400 mg every eight hours) in patients with HPS have shown mixed results regarding oxygenation, leaving the role of pentoxifylline unclear [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/64,65\" class=\"abstract_t\">64,65</a>]. In a pilot study of 10 children with HPS, pentoxifylline was given at a dose of 20 <span class=\"nowrap\">mg/kg/day</span> in three divided doses. Four children did not tolerate the drug due to severe vomiting and thrombocytopenia. The six children who completed the three-month trial demonstrated significant improvement in oxygenation; however, these improvements were not maintained after discontinuation of pentoxifylline [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/66\" class=\"abstract_t\">66</a>].</p><p>Various other medications have been tried, but anecdotal evidence and uncontrolled trials suggest that such medications cause little or no sustained improvement in oxygenation. Examples include <a href=\"topic.htm?path=methylene-blue-drug-information\" class=\"drug drug_general\">methylene blue</a>, N(G)-nitro-L-arginine methyl ester (L-NAME), curcumin, terlipressin, somatostatin analogues (eg, <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a>), <a href=\"topic.htm?path=nitric-oxide-drug-information\" class=\"drug drug_general\">nitric oxide</a> synthase inhibitors, cyclooxygenase inhibitors (eg, <a href=\"topic.htm?path=indomethacin-drug-information\" class=\"drug drug_general\">indomethacin</a>), almitrine bismesylate, antibiotics, chemotherapy (eg, <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a>), glucocorticoids, beta blockers (eg, <a href=\"topic.htm?path=propranolol-drug-information\" class=\"drug drug_general\">propranolol</a>), <a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information\" class=\"drug drug_general\">mycophenolate</a> mofetil, <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a>, and inhaled nitric oxide (<a href=\"image.htm?imageKey=PULM%2F52526\" class=\"graphic graphic_table graphicRef52526 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/1,8,66-73\" class=\"abstract_t\">1,8,66-73</a>].</p><p class=\"headingAnchor\" id=\"H308564\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hepatopulmonary syndrome (HPS) is characterized by the triad of abnormal arterial oxygenation caused by intrapulmonary vascular dilatations (IPVD) in the setting of liver disease, portal hypertension, or congenital portosystemic shunts. (See <a href=\"#H19912623\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>HPS is typically a progressive disorder, the presence of which worsens the prognosis of patients with cirrhosis and probably other liver diseases. It is rare for progressive hypoxemic respiratory failure to be the primary cause of death. Spontaneous resolution of HPS without treatment is unlikely. (See <a href=\"#H3217399\" class=\"local\">'Natural history'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The only definitive therapy for patients with HPS is liver transplantation. Other than long-term supplemental oxygen, there are no effective medical therapies for HPS (<a href=\"image.htm?imageKey=PULM%2F52526\" class=\"graphic graphic_table graphicRef52526 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/1,8\" class=\"abstract_t\">1,8</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For most patients with mild to moderate HPS (partial arterial pressure of oxygen [PaO<sub>2</sub>] &gt;60 mmHg [&gt;8 kPa]) (<a href=\"image.htm?imageKey=PULM%2F109898\" class=\"graphic graphic_table graphicRef109898 \">table 1</a>), we suggest surveillance with pulse oximetry every 6 to 12 months for disease progression. In addition, for those in whom it is indicated (<a href=\"image.htm?imageKey=PULM%2F76543\" class=\"graphic graphic_table graphicRef76543 \">table 3</a>), we suggest supplemental oxygen rather than liver transplantation (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Although liver transplantation is not routinely indicated in this population, we typically refer patients early in the course of their HPS for liver transplant evaluation, so that as HPS progresses, activation on the waitlist can be prompt. (See <a href=\"#H958610991\" class=\"local\">'Mild to moderate hepatopulmonary syndrome'</a> above.) </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For most patients with severe or very severe HPS, we recommend an expedited liver transplant evaluation together with oxygen supplementation (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). (See <a href=\"#H599838807\" class=\"local\">'Liver transplantation'</a> above.) </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Most patients (80 percent) improve following liver transplantation, although the time course for improvement is highly variable (days up to one year). Patients with refractory HPS following liver transplantation should be treated with high flow oxygen and evaluated for the development of portopulmonary hypertension or other conditions that may be contributing to hypoxemia. HPS rarely recurs after LT. (See <a href=\"#H306139326\" class=\"local\">'Refractory hepatopulmonary syndrome'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with HPS who are refractory to or not eligible for LT, options are limited and include investigational therapies such as transjugular intrahepatic portosystemic shunt (TIPS), coil embolization, and garlic. (See <a href=\"#H2506314191\" class=\"local\">'Investigational'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/1\" class=\"nounderline abstract_t\">Rodr&iacute;guez-Roisin R, Krowka MJ. Hepatopulmonary syndrome--a liver-induced lung vascular disorder. N Engl J Med 2008; 358:2378.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/2\" class=\"nounderline abstract_t\">Krowka MJ, Fallon MB, Kawut SM, et al. International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. Transplantation 2016; 100:1440.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/3\" class=\"nounderline abstract_t\">Schenk P, Sch&ouml;niger-Hekele M, Fuhrmann V, et al. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology 2003; 125:1042.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/4\" class=\"nounderline abstract_t\">Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: Impact of liver transplantation. Hepatology 2005; 41:1122.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/5\" class=\"nounderline abstract_t\">Pascasio JM, Grilo I, L&oacute;pez-Pardo FJ, et al. Prevalence and severity of hepatopulmonary syndrome and its influence on survival in cirrhotic patients evaluated for liver transplantation. Am J Transplant 2014; 14:1391.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/6\" class=\"nounderline abstract_t\">Krowka MJ, Dickson ER, Cortese DA. Hepatopulmonary syndrome. Clinical observations and lack of therapeutic response to somatostatin analogue. Chest 1993; 104:515.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/7\" class=\"nounderline abstract_t\">Fallon MB, Krowka MJ, Brown RS, et al. Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology 2008; 135:1168.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/8\" class=\"nounderline abstract_t\">Rodr&iacute;guez-Roisin R, Krowka MJ, Herv&eacute; P, et al. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J 2004; 24:861.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/9\" class=\"nounderline abstract_t\">Tzovaras N, Stefos A, Georgiadou SP, et al. Reversion of severe hepatopulmonary syndrome in a non cirrhotic patient after corticosteroid treatment for granulomatous hepatitis: a case report and review of the literature. World J Gastroenterol 2006; 12:336.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/10\" class=\"nounderline abstract_t\">Arguedas MR, Abrams GA, Krowka MJ, Fallon MB. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology 2003; 37:192.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/11\" class=\"nounderline abstract_t\">Krowka MJ, Mandell MS, Ramsay MA, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004; 10:174.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/12\" class=\"nounderline abstract_t\">Gupta S, Castel H, Rao RV, et al. Improved survival after liver transplantation in patients with hepatopulmonary syndrome. Am J Transplant 2010; 10:354.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/13\" class=\"nounderline abstract_t\">Schiffer E, Majno P, Mentha G, et al. Hepatopulmonary syndrome increases the postoperative mortality rate following liver transplantation: a prospective study in 90 patients. Am J Transplant 2006; 6:1430.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/14\" class=\"nounderline abstract_t\">Stoller JK, Lange PA, Westveer MK, et al. Prevalence and reversibility of the hepatopulmonary syndrome after liver transplantation. The Cleveland Clinic experience. West J Med 1995; 163:133.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/15\" class=\"nounderline abstract_t\">Collisson EA, Nourmand H, Fraiman MH, et al. Retrospective analysis of the results of liver transplantation for adults with severe hepatopulmonary syndrome. Liver Transpl 2002; 8:925.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/16\" class=\"nounderline abstract_t\">Taill&eacute; C, Cadranel J, Bellocq A, et al. Liver transplantation for hepatopulmonary syndrome: a ten-year experience in Paris, France. Transplantation 2003; 75:1482.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/17\" class=\"nounderline abstract_t\">Starzl TE, Groth CG, Brettschneider L, et al. Extended survival in 3 cases of orthotopic homotransplantation of the human liver. Surgery 1968; 63:549.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/18\" class=\"nounderline abstract_t\">Stoller JK, Moodie D, Schiavone WA, et al. Reduction of intrapulmonary shunt and resolution of digital clubbing associated with primary biliary cirrhosis after liver transplantation. Hepatology 1990; 11:54.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/19\" class=\"nounderline abstract_t\">Eriksson LS, S&ouml;derman C, Ericzon BG, et al. Normalization of ventilation/perfusion relationships after liver transplantation in patients with decompensated cirrhosis: evidence for a hepatopulmonary syndrome. Hepatology 1990; 12:1350.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/20\" class=\"nounderline abstract_t\">Barry S, Pingleton S, Kindscher J, et al. Comparison of shunt fractions pre- and post-liver transplantation. Transplant Proc 1993; 25:1801.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/21\" class=\"nounderline abstract_t\">Battaglia SE, Pretto JJ, Irving LB, et al. Resolution of gas exchange abnormalities and intrapulmonary shunting following liver transplantation. Hepatology 1997; 25:1228.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/22\" class=\"nounderline abstract_t\">Deberaldini M, Arcanjo AB, Melo E, et al. Hepatopulmonary syndrome: morbidity and survival after liver transplantation. Transplant Proc 2008; 40:3512.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/23\" class=\"nounderline abstract_t\">Iyer VN, Swanson KL, Cartin-Ceba R, et al. Hepatopulmonary syndrome: favorable outcomes in the MELD exception era. Hepatology 2013; 57:2427.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/24\" class=\"nounderline abstract_t\">Goldberg DS, Krok K, Batra S, et al. Impact of the hepatopulmonary syndrome MELD exception policy on outcomes of patients after liver transplantation: an analysis of the UNOS database. Gastroenterology 2014; 146:1256.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/25\" class=\"nounderline abstract_t\">Martin P, DiMartini A, Feng S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 2014; 59:1144.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/26\" class=\"nounderline abstract_t\">Fallon MB, Mulligan DC, Gish RG, Krowka MJ. Model for end-stage liver disease (MELD) exception for hepatopulmonary syndrome. Liver Transpl 2006; 12:S105.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/27\" class=\"nounderline abstract_t\">Saigal S, Choudhary N, Saraf N, et al. Excellent outcome of living donor liver transplantation in patients with hepatopulmonary syndrome: a single centre experience. Clin Transplant 2013; 27:530.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/28\" class=\"nounderline abstract_t\">Carey EJ, Douglas DD, Balan V, et al. Hepatopulmonary syndrome after living donor liver transplantation and deceased donor liver transplantation: a single-center experience. Liver Transpl 2004; 10:529.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/29\" class=\"nounderline abstract_t\">Irei T, Onoe T, Das LK, et al. Successful resolution of very severe hepatopulmonary syndrome following adult-to-adult living donor liver transplantation: Report of two cases. Hepatol Res 2014.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/30\" class=\"nounderline abstract_t\">Stanley NN, Williams AJ, Dewar CA, et al. Hypoxia and hydrothoraces in a case of liver cirrhosis: correlation of physiological, radiographic, scintigraphic, and pathological findings. Thorax 1977; 32:457.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/31\" class=\"nounderline abstract_t\">Martinez G, Barber&agrave; JA, Navasa M, et al. Hepatopulmonary syndrome associated with cardiorespiratory disease. J Hepatol 1999; 30:882.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/32\" class=\"nounderline abstract_t\">Krowka MJ, Wiesner RH, Heimbach JK. Pulmonary contraindications, indications and MELD exceptions for liver transplantation: a contemporary view and look forward. J Hepatol 2013; 59:367.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/33\" class=\"nounderline abstract_t\">Van Thiel DH, Schade RR, Gavaler JS, et al. Medical aspects of liver transplantation. Hepatology 1984; 4:79S.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/34\" class=\"nounderline abstract_t\">Mart&iacute;nez-Palli G, G&oacute;mez FP, Barber&agrave; JA, et al. Sustained low diffusing capacity in hepatopulmonary syndrome after liver transplantation. World J Gastroenterol 2006; 12:5878.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/35\" class=\"nounderline abstract_t\">Schwarzenberg SJ, Freese DK, Regelmann WE, et al. Resolution of severe intrapulmonary shunting after liver transplantation. Chest 1993; 103:1271.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/36\" class=\"nounderline abstract_t\">Lange PA, Stoller JK. The hepatopulmonary syndrome. Effect of liver transplantation. Clin Chest Med 1996; 17:115.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/37\" class=\"nounderline abstract_t\">Al-Hussaini A, Taylor RM, Samyn M, et al. Long-term outcome and management of hepatopulmonary syndrome in children. Pediatr Transplant 2010; 14:276.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/38\" class=\"nounderline abstract_t\">Rodriguez-Roisin R, Krowka MJ. Is severe arterial hypoxaemia due to hepatic disease an indication for liver transplantation? A new therapeutic approach. Eur Respir J 1994; 7:839.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/39\" class=\"nounderline abstract_t\">Fallon MB. Hepatopulmonary syndrome: more than just a matter of tone? Hepatology 2006; 43:912.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/40\" class=\"nounderline abstract_t\">Aucejo F, Miller C, Vogt D, et al. Pulmonary hypertension after liver transplantation in patients with antecedent hepatopulmonary syndrome: a report of 2 cases and review of the literature. Liver Transpl 2006; 12:1278.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/41\" class=\"nounderline abstract_t\">Koch DG, Caplan M, Reuben A. Pulmonary hypertension after liver transplantation: case presentation and review of the literature. Liver Transpl 2009; 15:407.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/42\" class=\"nounderline abstract_t\">Nayyar D, Man HS, Granton J, et al. Proposed management algorithm for severe hypoxemia after liver transplantation in the hepatopulmonary syndrome. Am J Transplant 2015; 15:903.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/43\" class=\"nounderline abstract_t\">Nayyar D, Man HS, Granton J, Gupta S. Defining and characterizing severe hypoxemia after liver transplantation in hepatopulmonary syndrome. Liver Transpl 2014; 20:182.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/44\" class=\"nounderline abstract_t\">Meyers C, Low L, Kaufman L, et al. Trendelenburg positioning and continuous lateral rotation improve oxygenation in hepatopulmonary syndrome after liver transplantation. Liver Transpl Surg 1998; 4:510.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/45\" class=\"nounderline abstract_t\">Karnatovskaia LV, Matharu J, Burger C, Keller CA. Inhaled nitric oxide as a potential rescue therapy for persistent hepatopulmonary syndrome after liver transplantation. Transplantation 2014; 98:e64.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/46\" class=\"nounderline abstract_t\">Roma J, Balbi E, Pacheco-Moreira L, et al. Methylene blue used as a bridge to liver transplantation postoperative recovery: a case report. Transplant Proc 2010; 42:601.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/47\" class=\"nounderline abstract_t\">Lee HW, Suh KS, Kim J, et al. Pulmonary artery embolotherapy in a patient with type I hepatopulmonary syndrome after liver transplantation. Korean J Radiol 2010; 11:485.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/48\" class=\"nounderline abstract_t\">Auzinger G, Willars C, Loveridge R, et al. Extracorporeal membrane oxygenation for refractory hypoxemia after liver transplantation in severe hepatopulmonary syndrome: a solution with pitfalls. Liver Transpl 2014; 20:1141.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/49\" class=\"nounderline abstract_t\">O'Leary JG, Rees CR, Klintmalm GB, Davis GL. Inferior vena cava stent resolves hepatopulmonary syndrome in an adult with a spontaneous inferior vena cava-portal vein shunt. Liver Transpl 2009; 15:1897.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/50\" class=\"nounderline abstract_t\">Sahu MK, Bisoi AK, Chander NC, et al. Abernethy syndrome, a rare cause of hypoxemia: A case report. Ann Pediatr Cardiol 2015; 8:64.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/51\" class=\"nounderline abstract_t\">Chevallier P, Novelli L, Motamedi JP, et al. Hepatopulmonary syndrome successfully treated with transjugular intrahepatic portosystemic shunt: a three-year follow-up. J Vasc Interv Radiol 2004; 15:647.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/52\" class=\"nounderline abstract_t\">Paramesh AS, Husain SZ, Shneider B, et al. Improvement of hepatopulmonary syndrome after transjugular intrahepatic portasystemic shunting: case report and review of literature. Pediatr Transplant 2003; 7:157.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/53\" class=\"nounderline abstract_t\">Lasch HM, Fried MW, Zacks SL, et al. Use of transjugular intrahepatic portosystemic shunt as a bridge to liver transplantation in a patient with severe hepatopulmonary syndrome. Liver Transpl 2001; 7:147.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/54\" class=\"nounderline abstract_t\">Selim KM, Akriviadis EA, Zuckerman E, et al. Transjugular intrahepatic portosystemic shunt: a successful treatment for hepatopulmonary syndrome. Am J Gastroenterol 1998; 93:455.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/55\" class=\"nounderline abstract_t\">Ben&iacute;tez C, Arrese M, Jorquera J, et al. Successful treatment of severe hepatopulmonary syndrome with a sequential use of TIPS placement and liver transplantation. Ann Hepatol 2009; 8:71.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/56\" class=\"nounderline abstract_t\">Nistal MW, Pace A, Klose H, et al. Hepatopulmonary syndrome caused by sarcoidosis of the liver treated with transjugular intrahepatic portosystemic shunt. Thorax 2013; 68:889.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/57\" class=\"nounderline abstract_t\">Tsauo J, Weng N, Ma H, et al. Role of Transjugular Intrahepatic Portosystemic Shunts in the Management of Hepatopulmonary Syndrome: A Systemic Literature Review. J Vasc Interv Radiol 2015; 26:1266.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/58\" class=\"nounderline abstract_t\">Martinez-Palli G, Drake BB, Garcia-Pagan JC, et al. Effect of transjugular intrahepatic portosystemic shunt on pulmonary gas exchange in patients with portal hypertension and hepatopulmonary syndrome. World J Gastroenterol 2005; 11:6858.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/59\" class=\"nounderline abstract_t\">Saad NE, Lee DE, Waldman DL, Saad WE. Pulmonary arterial coil embolization for the management of persistent type I hepatopulmonary syndrome after liver transplantation. J Vasc Interv Radiol 2007; 18:1576.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/60\" class=\"nounderline abstract_t\">Grady K, Gowda S, Kingah P, Soubani AO. Coil embolization of pulmonary arteries as a palliative treatment of diffuse type I hepatopulmonary syndrome. Respir Care 2015; 60:e20.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/61\" class=\"nounderline abstract_t\">De BK, Dutta D, Pal SK, et al. The role of garlic in hepatopulmonary syndrome: a randomized controlled trial. Can J Gastroenterol 2010; 24:183.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/62\" class=\"nounderline abstract_t\">Tieppo J, Cuevas MJ, Vercelino R, et al. Quercetin administration ameliorates pulmonary complications of cirrhosis in rats. J Nutr 2009; 139:1339.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/63\" class=\"nounderline abstract_t\">Sztrymf B, Rabiller A, Nunes H, et al. Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats. Eur Respir J 2004; 23:752.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/64\" class=\"nounderline abstract_t\">Tanikella R, Philips GM, Faulk DK, et al. Pilot study of pentoxifylline in hepatopulmonary syndrome. Liver Transpl 2008; 14:1199.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/65\" class=\"nounderline abstract_t\">Gupta LB, Kumar A, Jaiswal AK, et al. Pentoxifylline therapy for hepatopulmonary syndrome: a pilot study. Arch Intern Med 2008; 168:1820.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/66\" class=\"nounderline abstract_t\">Kianifar HR, Khalesi M, Mahmoodi E, Afzal Aghaei M. Pentoxifylline in hepatopulmonary syndrome. World J Gastroenterol 2012; 18:4912.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/67\" class=\"nounderline abstract_t\">Schenk P, Madl C, Rezaie-Majd S, et al. Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med 2000; 133:701.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/68\" class=\"nounderline abstract_t\">Castro M, Krowka MJ. Hepatopulmonary syndrome. A pulmonary vascular complication of liver disease. Clin Chest Med 1996; 17:35.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/69\" class=\"nounderline abstract_t\">Fallon MB, Abrams GA. Pulmonary dysfunction in chronic liver disease. Hepatology 2000; 32:859.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/70\" class=\"nounderline abstract_t\">Brussino L, Bucca C, Morello M, et al. Effect on dyspnoea and hypoxaemia of inhaled N(G)-nitro-L-arginine methyl ester in hepatopulmonary syndrome. Lancet 2003; 362:43.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/71\" class=\"nounderline abstract_t\">Almeida JA, Riordan SM, Liu J, et al. Deleterious effect of nitric oxide inhibition in chronic hepatopulmonary syndrome. Eur J Gastroenterol Hepatol 2007; 19:341.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/72\" class=\"nounderline abstract_t\">Song JY, Choi JY, Ko JT, et al. Long-term aspirin therapy for hepatopulmonary syndrome. Pediatrics 1996; 97:917.</a></li><li><a href=\"https://www.uptodate.com/contents/hepatopulmonary-syndrome-in-adults-natural-history-treatment-and-outcomes/abstract/73\" class=\"nounderline abstract_t\">Moreira Silva H, Reis G, Guedes M, et al. A case of hepatopulmonary syndrome solved by mycophenolate mofetil (an inhibitor of angiogenesis and nitric oxide production). J Hepatol 2013; 58:630.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 16175 Version 13.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H308564\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H19912623\" id=\"outline-link-H19912623\">INTRODUCTION</a></li><li><a href=\"#H3217399\" id=\"outline-link-H3217399\">NATURAL HISTORY</a></li><li><a href=\"#H19913348\" id=\"outline-link-H19913348\">TREATMENT AND PROGNOSIS</a><ul><li><a href=\"#H958610991\" id=\"outline-link-H958610991\">Mild to moderate hepatopulmonary syndrome</a><ul><li><a href=\"#H1723871244\" id=\"outline-link-H1723871244\">- Observation</a></li><li><a href=\"#H1079173587\" id=\"outline-link-H1079173587\">- Oxygen supplementation</a></li></ul></li><li><a href=\"#H4166728594\" id=\"outline-link-H4166728594\">Severe or very severe hepatopulmonary syndrome</a><ul><li><a href=\"#H3022257422\" id=\"outline-link-H3022257422\">- Oxygen supplementation</a></li><li><a href=\"#H599838807\" id=\"outline-link-H599838807\">- Liver transplantation</a><ul><li><a href=\"#H458149789\" id=\"outline-link-H458149789\">Mortality</a></li><li><a href=\"#H708385551\" id=\"outline-link-H708385551\">Prognostic factors</a></li><li><a href=\"#H1666972769\" id=\"outline-link-H1666972769\">Oxygenation</a></li><li><a href=\"#H1702366810\" id=\"outline-link-H1702366810\">Follow-up</a></li></ul></li></ul></li><li><a href=\"#H306139326\" id=\"outline-link-H306139326\">Refractory hepatopulmonary syndrome</a></li><li><a href=\"#H1624424311\" id=\"outline-link-H1624424311\">Other therapies</a></li></ul></li><li><a href=\"#H2506314191\" id=\"outline-link-H2506314191\">INVESTIGATIONAL</a><ul><li><a href=\"#H2056034072\" id=\"outline-link-H2056034072\">Transjugular intrahepatic portosystemic shunt</a></li><li><a href=\"#H2558039825\" id=\"outline-link-H2558039825\">Embolization</a></li><li><a href=\"#H4182446133\" id=\"outline-link-H4182446133\">Vasoactive medications</a><ul><li><a href=\"#H940337831\" id=\"outline-link-H940337831\">- Garlic (allium sativum)</a></li><li><a href=\"#H2560738277\" id=\"outline-link-H2560738277\">- Others</a></li></ul></li></ul></li><li><a href=\"#H308564\" id=\"outline-link-H308564\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PULM/16175|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=RADIOL/89203\" class=\"graphic graphic_diagnosticimage\">- Hepatopulmonary syndrome and pulmonary AVM coil embolization</a></li></ul></li><li><div id=\"PULM/16175|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/109898\" class=\"graphic graphic_table\">- Severity of hepatopulmonary syndrome</a></li><li><a href=\"image.htm?imageKey=PULM/52526\" class=\"graphic graphic_table\">- Efficacy of treatment in HPS</a></li><li><a href=\"image.htm?imageKey=PULM/76543\" class=\"graphic graphic_table\">- LTOT indications</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=hepatopulmonary-syndrome-in-adults-prevalence-causes-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Hepatopulmonary syndrome in adults: Prevalence, causes, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infectious-complications-in-liver-transplantation\" class=\"medical medical_review\">Infectious complications in liver transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=liver-transplantation-in-adults-long-term-management-of-transplant-recipients\" class=\"medical medical_review\">Liver transplantation in adults: Long-term management of transplant recipients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=liver-transplantation-in-adults-patient-selection-and-pretransplantation-evaluation\" class=\"medical medical_review\">Liver transplantation in adults: Patient selection and pretransplantation evaluation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=liver-transplantation-diagnosis-of-acute-cellular-rejection\" class=\"medical medical_review\">Liver transplantation: Diagnosis of acute cellular rejection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=long-term-supplemental-oxygen-therapy\" class=\"medical medical_review\">Long-term supplemental oxygen therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mechanical-ventilation-of-adults-in-acute-respiratory-distress-syndrome\" class=\"medical medical_review\">Mechanical ventilation of adults in acute respiratory distress syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=model-for-end-stage-liver-disease-meld\" class=\"medical medical_review\">Model for End-stage Liver Disease (MELD)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-pulmonary-function-testing-in-adults\" class=\"medical medical_review\">Overview of pulmonary function testing in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=portopulmonary-hypertension\" class=\"medical medical_review\">Portopulmonary hypertension</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pulse-oximetry\" class=\"medical medical_review\">Pulse oximetry</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=therapeutic-approach-to-adult-patients-with-pulmonary-arteriovenous-malformations\" class=\"medical medical_review\">Therapeutic approach to adult patients with pulmonary arteriovenous malformations</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications\" class=\"medical medical_review\">Transjugular intrahepatic portosystemic shunts: Indications and contraindications</a></li></ul></div></div>","javascript":null}